Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug 1;7(8):e2428953.
doi: 10.1001/jamanetworkopen.2024.28953.

Thiazide Dose, Urine Calcium, and Symptomatic Kidney Stone Events

Ryan S Hsi  1 , Phyllis L Yan  2 , Naim M Maalouf  3   4 , Sara L Best  5   6 , John R Asplin  6 , Vahakn Shahinian  2   7 , John M Hollingsworth  8
Affiliations

Thiazide Dose, Urine Calcium, and Symptomatic Kidney Stone Events

Ryan S Hsi et al. JAMA Netw Open. .
No abstract available

Plain language summary

This cohort study examines the association between thiazide dose and urine calcium reduction and correlates urine calcium changes with the occurrence of symptomatic kidney stone events.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: None reported.

Figures

Figure 1.
Figure 1.. Adjusted Mean Absolute and Percentage Change in Urine Calcium by Daily Thiazide Dose
Doses are classified as low (<12.5 mg/d chlorthalidone, <0.6125 mg/d indapamide, <25 mg/d hydrochlorothiazide), medium (12.5 to <25 mg/d chlorthalidone, 0.6125 to <1.25 mg/d indapamide, 25 to <50 mg/d hydrochlorothiazide), and high (≥25 mg/d chlorthalidone, ≥1.25 mg/d indapamide, ≥50 mg/d hydrochlorothiazide). Error bars indicate 95% CIs.
Figure 2.
Figure 2.. Kaplan-Meier Curves of Cumulative Incidence of a Symptomatic Stone Event at 4 Years of Follow-Up Across Individuals by Terciles
With low or minimal (mean [SD], 24 [61] mg/d), intermediate (mean [SD], −90 [25] mg/d), and high (mean [SD], −216 [74] mg/d) reductions in urine calcium.
See this image and copyright information in PMC

Comment in

References

    1. Fink HA, Wilt TJ, Eidman KE, et al. . Medical management to prevent recurrent nephrolithiasis in adults: a systematic review for an American College of Physicians Clinical Guideline. Ann Intern Med. 2013;158(7):535-543. doi:10.7326/0003-4819-158-7-201304020-00005 - DOI - PubMed
    1. Dhayat NA, Bonny O, Roth B, et al. . Hydrochlorothiazide and prevention of kidney-stone recurrence. N Engl J Med. 2023;388(9):781-791. doi:10.1056/NEJMoa2209275 - DOI - PubMed
    1. Bargagli M, Trelle S, Bonny O, Fuster DG. Thiazides for kidney stone recurrence prevention. Curr Opin Nephrol Hypertens. 2024;33(4):427-432. doi:10.1097/MNH.0000000000000990 - DOI - PMC - PubMed
    1. Krampe NA, Oerline MK, Asplin JR, et al. . Potential for urolithiasis-related research using the novel Medicare-Litholink Database. Urol Pract. 2023;10(2):147-152. doi:10.1097/UPJ.0000000000000378 - DOI - PMC - PubMed
    1. Hsi RS, Yan PL, Crivelli JJ, Goldfarb DS, Shahinian V, Hollingsworth JM. Comparison of selective vs empiric pharmacologic preventive therapy of kidney stone recurrence with high-risk features. Urology. 2022;164:74-79. doi:10.1016/j.urology.2021.12.037 - DOI - PMC - PubMed

Publication types